The Phase II SKYSCRAPER-04 trial evaluated the efficacy of atezolizumab combined with the anti-TIGIT antibody tiragolumab in patients with PD-L1-positive cervical cancer (TAP ≥ 5%) receiving second- or third-line treatment [82]. Here, CD274 is linked to cervical cancer.